Cynata Therapeutics Limited announced that the appointment of Dr. Kilian Kelly to the position of Chief Executive Officer, Effective on July 1, 2023, following the retirement of Dr. Ross Macdonald. Dr. Kelly has been Cynata's Chief Operating Officer since May 2019 and has been instrumental in advancing the Company's clinical pipeline since joining Cynata as Vice President, Product Development in 2014.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.21 AUD | 0.00% | 0.00% | +68.00% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+68.00% | 24.6M | |
-2.76% | 103B | |
+1.34% | 95.28B | |
+1.46% | 22.15B | |
-15.87% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.33% | 16.05B | |
+4.84% | 13.68B | |
+32.94% | 12.17B |
- Stock Market
- Equities
- CYP Stock
- News Cynata Therapeutics Limited
- Cynata Therapeutics Limited Announces Chief Executive Officer Changes